Methods of treating fungal infections
Methods of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more antifungal peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7 are described. Antifungal pharmaceutical compositions and dosage forms, including field-deployable dosage forms, comprising one or more of these antifungal peptides are also described.
1. A pharmaceutical composition comprising one or more peptides selected from the group consisting of Kn2-7, dKn2-7, BmKn2, and dBmKn2, wherein said BmKn2 and said Kn2-7 peptides comprise a combination of D form and L form amino acids; wherein said pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, excipients or diluents, and wherein said one or more peptides are present in an amount sufficient to treat a fungal infection in a subject in need thereof.
2. The pharmaceutical composition of claim 1 , wherein said amount sufficient to treat a fungal infection in a subject in need thereof is from about 6 μmL to about 5 mg/mL.
3. The pharmaceutical composition of claim 1 , further comprising one or more additional pharmaceutically acceptable agents.
4. The pharmaceutical composition of claim 3 , wherein the one or more additional pharmaceutically acceptable agents is selected from the group consisting of an antimicrobial agent, an analgesic, a wound healing agent, a biofilm dispersal agent, and a biofilm inhibitor agent.
5. The pharmaceutical composition of claim 4 , wherein the antimicrobial agent is selected from the group consisting of an antifungal agent, an antibacterial agent, and an antiviral agent.
6. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is a dosage form designed for topical administration.
7. The pharmaceutical composition of claim 6 , wherein said dosage form designed for topical administration is a wound dressing.
8. The pharmaceutical composition of claim 7 , wherein said wound dressing is a field-deployable wound dressing.
9. The pharmaceutical composition of claim 6 , wherein said dosage form designed for topical administration comprises electrospun and/or wet-spun fibers.
10. The pharmaceutical composition of claim 9 , wherein said wet-spun fibers comprise 2% alginate (w/v), 2% alginate/0.1% chitosan oligosaccharide lactate, or 2% alginate/0.2% chitosan oligosaccharide lactate.
11. A method of treating a polymicrobial infection and/or a fungal infection in a subject in need thereof comprising administering to the subject the pharmaceutical composition of any one of claims 1 - 10 .